What Planet Innovation does

Planet Innovation is a privately held healthtech innovation and contract development and manufacturing organization (CDMO) founded in 2009 in Melbourne, Australia, with a US headquarters in Irvine, California. The company provides end-to-end product development, commercialization, digital, and manufacturing services to enterprise clients across diagnostics, life sciences, and healthcare technology — spanning instrument design, electronics, software/firmware, optics, systems engineering, human factors, regulatory affairs, and FDA-registered manufacturing under ISO 13485:2016 and ISO 9001 certifications across approximately 100,000 sq. ft. of facilities including ISO 7 cleanrooms.

The company's revenue model blends professional services (fee-for-service design, engineering, regulatory, and commercialization engagements) with hardware sales from contract manufacturing of regulated medical instruments and consumables, plus digital services revenue from custom connected-health and IoT platforms. Pricing is bespoke and quote-based with multi-year contracts, and the GTM is enterprise field sales supported by dedicated product managers. Notable manufactured products include the Geri IVF Imaging Incubator and Gavi embryo-freezing instrument (Genea Biomedx), the ASP Health automated sample preparation platform, the Rotea counterflow centrifugation system (Scinogy/Gibco CTS), the Truvian TruVerus benchtop blood testing platform, the AVATAR Foundry solid-tumor cell therapy instrument (Xcell Biosciences), the SLIDEVIEW DX VS-M1 digital pathology scanner (Evident), the Dermapen 4 micro-needling device (DermapenWorld, 50,000+ units shipped to 100+ countries), and the Ramsay Health Care non-invasive patient monitoring system. Production capacity is demonstrated at 1,000 instruments per month for a single global diagnostics client.

Planet Innovation serves a concentrated base of enterprise healthtech clients including Abbott, Bio-Rad, Merck, IDEX Health & Science, Meridian Bioscience, Truvian, Genea Biomedx, and DermapenWorld, with over 90% repeat customer engagement. Recent strategic actions — the 2023 acquisition of BIT USA, the July 2025 Meiban Corp Holdings strategic alliance (with Meiban taking a ~20% equity stake to extend manufacturing into Asia), the February 2025 RANGER consortium partnership with Ginkgo Bioworks ($25.1M program), and the October 2025 Precision Cell Systems cell-analysis ecosystem partnership — position the company as a scaled, geographically distributed MedTech CDMO with growing regulatory and ecosystem leverage.

Name

Planet Innovation

Legal name

Planet Innovation Pty Ltd

Website

https://planetinnovation.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

251–500 employees

Short description

Planet Innovation is a privately held healthtech CDMO offering end-to-end product design, engineering, digital, and FDA-registered manufacturing services to enterprise diagnostics, life sciences, and medical device companies across the US, Australia, and Asia.

Ownership category

akta.pro rank

Product category

Healthtech Contract Development and Manufacturing (CDMO)

NAICS

Scientific Research and Development Services (5417), Medical Equipment and Supplies Manufacturing (33911), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Process Development & Tech Transfer Services (CDMO) (HLAGABAL)

akta.pro secondary industry

Cell Therapy CDMO (HLAGABAD)

Keywords

• Medical device development
• Contract manufacturing services
• Healthtech product design
• Diagnostic instrument manufacturing
• Medical device commercialization

Headquarters

HQ city

Lake Forest

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Contract Development Services: Fee-for-service product development engagements covering design, engineering, regulatory strategy, and commercialization support. PI provides personalized service with flexible engagement models that can scale up or down based on client needs.
2. Contract Manufacturing Services: Manufacturing of regulated medical instruments and consumables ranging from low-complexity devices to large floor-standing IVD instruments. Revenue generated through production contracts with flexible supply and quality agreements.
3. Digital Services: Customized digital health and IoT solutions for regulated medical environments, including platform development, managed operations, and launch management services.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Planet Innovation is a healthtech-focused contract development and manufacturing organization (CDMO) that delivers end-to-end services spanning product development, commercialization, digital services, and regulated manufacturing for the diagnostics, life sciences, and healthcare industries. The company combines industrial design, mechanical/electronics/software engineering, regulatory strategy, and FDA-registered ISO 13485 manufacturing under one roof to take connected medical devices, IVD instruments, and digital health solutions from concept through commercial production.

Product overview

Planet Innovation is a healthtech innovation and contract development and manufacturing organization (CDMO) offering end-to-end services spanning product development, commercialization, digital services, and manufacturing for the diagnostics, life sciences, and healthcare industries. The company provides both as-a-service capabilities and manufactured products including connected healthcare instruments (Geri IVF Imaging Incubator, ASP Health sample preparation platform, Truvian blood testing platform), cell therapy manufacturing systems (Rotea, AVATAR Foundry), digital health solutions (QBOX IVF, Non-invasive Patient Monitoring System, Zen HQ), diagnostic platforms (Proof Lab Test System, VIP2000), and consumables. The portfolio includes products developed in partnership with clients such as Abbott, ASP Health, Genea Biomedx, Merck, Ramsay Health Care, Truvian, Xcell Biosciences, and Evident, with manufacturing capabilities spanning instruments and consumables across approximately 100,000 sq. ft. of FDA-registered facilities in Irvine, California and Melbourne, Australia.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Over 90% repeat customer engagement rate
• +3 more outcomes

Named customers14 records

Segments4 records

Ideal customer profiles4 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Partnerships

17 partnerships are on record, tiered core, flagship and minor.

• Precision Cell Systems (PCS)coreStrategic or Co-development Partner · 1 October 2025Unique partnership model where PI provides extensive product development capacity through its 300+ experts and access to global manufacturing facilities in USA, Australia and Singapore. PCS consolidates cell analysis technologies and supports them with common commercial and operational infrastructure, eliminating substantial overhead costs for emerging technology companies. PI scales manufacturing up as PCS achieves commercial traction.
• Meiban Corp HoldingsflagshipStrategic or Co-development Partner · 1 July 2025Strategic alliance between PI and Meiban to deliver comprehensive CDMO services spanning from early-stage innovation through high-volume manufacturing. PI brings innovation, design, and early-stage manufacturing from Australia and USA; Meiban provides world-class automated mass manufacturing through 18 sites in Singapore and Malaysia with vertically integrated capabilities including plastic injection molding and PCB assembly. Meiban takes approximately 20% equity stake in Planet Innovation. This partnership creates one of the strongest offerings in the MedTech CDMO space.
• Quantum-SicoreTechnology or Integration · 1 January 2025Partnership for development and manufacturing of QSI's next generation protein sequencing instrument. PI brings product development and manufacturing expertise to support Quantum-Si's innovative benchtop next-gen protein sequencing instrument for clinical proteomics and pathogen detection.
• Ginkgo BioworksflagshipStrategic or Co-development Partner · 1 January 2025PI selected as key technology partner in USD $25.1 million RANGER consortium led by Ginkgo Bioworks to develop rapid, point-of-care, sequencing-based test for respiratory pathogens. The RANGER (Rapid Next-Generation Sequencing for Effective Medical Response) program aims to develop metagenomic sequencing solution with 6-hour turnaround time for hospitals and healthcare facilities.
• Jumpcode GenomicscoreTechnology or Integration · 1 January 2025Partner in RANGER consortium providing CRISPR-based technology for the Cipher system developed by PI. Jumpcode's technology enables comprehensive pathogen detection.
• BugSeqcoreTechnology or Integration · 1 January 2025Partner in RANGER consortium providing clinically-tailored bioinformatics platform for rapid metagenomic sequencing for infectious disease diagnostics.
• TGen (The Translational Genomics Research Institute) - Part of City of HopecoreStrategic or Co-development Partner · 1 January 2025Partner in RANGER consortium contributing translational research expertise. TGen published findings with Jumpcode on initial version of the system being developed.
• QbD GroupminorImplementation/ SI/ Consulting Partner · 1 January 2025Medical device regulatory specialists collaborating with consortium to secure EU certification and validation for the RANGER device before market entry.
• Xcell Biosciences (XcellBio)coreStrategic or Co-development Partner · 1 January 2023PI developed and manufactured the AVATAR Foundry instrument - world-first technology that grows cell therapies under unique conditions to target solid tumor cancers. XcellBio was named finalist in International Design Excellence Awards 2025 for this instrument. In March 2025, XcellBio announced agreement with Royal Perth Hospital for trial focused on rapid manufacturing of more potent cancer-killing cell therapies.
• EvidentcoreStrategic or Co-development Partner · 1 January 2023Partnership to develop and manufacture innovative digital workflow solutions for life science markets. Resulted in SLIDEVIEW DX VS-M1 scanner winning Design and Usability award at International Scanner Benchmark 2025.
• BIT GroupcoreStrategic or Co-development Partner · 1 January 2023PI acquired BIT Group's North American operations (BIT USA) based in Irvine, California, adding 29,000 sq. ft. facility and doubling PI's medtech manufacturing capacity.
• S2 GenomicsminorStrategic or Co-development PartnerCell analysis technology company acquired by PCS as part of the cell analysis ecosystem consolidation. PI provides manufacturing support through its partnership with PCS.
• ORFLOminorStrategic or Co-development PartnerCell analysis technology company acquired by PCS. PI provides manufacturing support through its partnership with PCS.
• BennuBiominorStrategic or Co-development PartnerCell analysis technology company acquired by PCS. PI provides manufacturing support through its partnership with PCS.
• DermapenWorldcoreStrategic or Co-development PartnerFull-service commercialization partnership with DermapenWorld. PI initially provided electronics and software services, then expanded to become manufacturing partner. PI has manufactured approximately 70,000 Dermapen microneedling devices shipped to over 100 countries worldwide. Product backed by 7-year warranty reflecting manufacturing reliability.
• Ramsay Health CarecoreStrategic or Co-development PartnerPartnership to improve patient safety in general wards through non-invasive patient monitoring system using sensors connected to real-time algorithmic decision support tools to detect early signs of patient deterioration and falls.
• Clever Culture SystemscoreStrategic or Co-development PartnerPI developed and manufactured APAS Independence - standalone automated culture plate reading instrument that received MDEA Silver Award and multiple Good Design Awards.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• Donatelle: Donatelle is a US-based medical device contract manufacturer offering design, prototyping, injection molding and assembly for Class I-III devices. Comparable to PI's US-based medical device manufacturing capability though smaller in scale and more focused on plastics-driven devices than diagnostics instruments.

Direct peers

• Phillips-Medisize: Phillips-Medisize (a Molex company) is a global MedTech CDMO providing design, development and manufacturing of medical devices and drug delivery products. Direct peer to PI given overlapping regulated medical device CDMO capabilities across diagnostics, connected health and life sciences instruments.
• Resonetics: Resonetics is a medical device contract manufacturer specializing in diagnostic and interventional medical technologies with capabilities in nitinol, laser processing, and finished device assembly. Comparable niche medical device CDMO positioning to PI's diagnostics and connected health focus.
• StarFish Medical: StarFish Medical is a Canadian medical device design and manufacturing services firm serving diagnostics and life science instrumentation companies. Closely comparable to PI's integrated design-through-manufacturing model for IVD and life sciences instruments.
• Cambridge Consultants: Cambridge Consultants is a UK-based product development and engineering firm with deep medical and life sciences practice covering IVD, connected health and surgical devices. Comparable to PI on the innovation and product development services side of the CDMO value chain.
• Meiban Corp Holdings: Meiban is a Singapore-headquartered precision contract manufacturer with 18 facilities across Singapore and Malaysia offering plastic injection molding, PCB assembly and full product assembly. Became PI's strategic alliance partner and ~20% shareholder in July 2025 to deliver end-to-end MedTech CDMO services, making it both partner and adjacent competitor.

Broad incumbents

• Jabil Healthcare: Jabil's Healthcare division is one of the largest global medical device and diagnostics CDMOs, offering design, manufacturing and supply chain services to leading OEMs. Comparable to PI's enterprise CDMO model but at materially larger scale and broader geographic reach.
• Flex (Flextronics): Flex operates a global Health Solutions business providing design, manufacturing and supply chain services for medical devices, diagnostics and connected health products. Overlaps PI's end-to-end MedTech CDMO offering but at much greater scale and broader industry exposure.
• Sanmina: Sanmina provides integrated manufacturing solutions including medical device and diagnostics manufacturing, with FDA-registered facilities globally. Comparable to PI's regulated medical device manufacturing capability, though Sanmina operates at much larger scale across multiple end markets.
• Celestica: Celestica's Healthcare & Life Sciences segment provides design, manufacturing and supply chain solutions for medical devices, diagnostics and connected health OEMs. Comparable regulated medical device CDMO services but operating at much greater global scale than PI.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/planetinnovate
• LinkedInlinkedin.com/company/planet-innovation-pty-ltd

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Planet Innovation